anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy will be 4 weeks following the initial dose of study drug on Cycle 1 Day 1. There will be 2 \~ 6 days between dose escalations to allow sufficient time for an adequate safety review. The max. dose may be lower than 400 mg. In the first dosing group of Part A (Cohort A1), subject dosing will be staggered such that administration of the first dose is separated by at least 7 days between the first 2 subjects. In each of Cohorts A1 to A5, 3 to 6 subjects will receive ZB716 doses according to the assigned dose level in the fasted state. For Cohort A6, Period 1, doses will be administered in the fasted state in Treatment Period 1 and 2, doses will be given 30 min. after starting a standard high fat breakfast.
The present invention prevents the congestion of a storage area required for each server to execute processing, and implements seamless processing. A medical image management system comprises a plurality of servers, a determination means, a transfer destination determination unit, and a transfer processing means. The plurality of servers are each provided with a storage unit for storing medical images to which supplementary information is attached, and execute image processing with respect to a medical image designated from a client. The determination means determines whether or not to transfer the medical image on the basis of the free space required for image processing and the free space in the storage unit of a server. The transfer destination determination unit determines the transfer destination server for transfer of the medical image. The transfer processing means transfers the medical image to be used in image processing to the server determined by the transfer destination determination unit.
An effectiveness-implementation sequential explanatory hybrid design type 2 using mixed methods was performed in 2020 and 2021 in two study sites: Pueblo Rico, Risaralda, and Rovira, Tolima. A quasi-experimental study with historical control (standard of care) was designed to evaluate the effectiveness of the community-based intervention supported by mHealth, in terms of monitoring of treatment of patients with cutaneous leishmaniasis. The effectiveness indicators i. number of follow-up contacts, ii. Adherence to treatment, iii. adverse drug reactions, and iv. the therapeutic response were compared between the intervention and control groups.

After the effectiveness evaluation was completed, three outcomes were assessed to inform the implementation of the community-based use of the app: acceptability, usability, and fidelity.
A charging device for a physiological signal transmitter is disclosed, wherein the physiological signal transmitter is to receive and externally transmit a physiological signal from a subcutaneous tissue of a living body, and has a first electrical connecting port. The charging device comprises a transmitter placing seat, a charging module and a locking module. The transmitter placing seat includes a bearing surface, and a first opening. The bearing surface disposes thereon the physiological signal transmitter; and the first opening aligns therewith the first electrical connecting port of the physiological signal transmitter. The charging module includes a second electrical connecting port, a third electrical connecting port and a circuit assembly. The second electrical connecting port is disposed in the first opening and moveable between a first position and a second position. The third electrical connecting port is for connecting thereto a power source. The circuit assembly is for performing charging and charging control on the physiological signal transmitter, and the circuit assembly is electrically connected to the second electrical connecting port and the third electrical connecting port. The locking module is extendable or retractable on the bearing surface for releasably positioning the physiological signal transmitter, wherein the charging module is driven to move the second electrical connecting port from the first position to the second position to be electrically connected to the first electrical connecting port, and the locking module is driven to protrude out of the bearing surface to fix the transmitter.
INTRODUCTION: Persistent inflammation, immunosuppression, and catabolism syndrome (PICS) has been proposed as an endotype of chronic critical illness (CCI). The aim of this systematic review is to synthesise the available evidence of risk factors, biomarkers, and biological mechanisms underlying PICS.
METHODS: MEDLINE, CENTRAL, and EMBASE were searched on June 2, 2023. Our population of interest was adult intensive care unit survivors. The exposure group was patients with PICS and the comparator group was patients with no PICS, CCI, or rapid recovery. Mean differences were pooled for each biomarker using a random effects DerSimonian-Laird method. Risk of bias assessment was done using the Newcastle-Ottawa Scale.
RESULTS: Six papers were included. Five were single-centre retrospective cohort studies, and one was a prospective cohort study, with sample sizes ranging from 22 to 391 patients. Two studies showed an increased incidence of PICS with age, and two studies showed an association between PICS and Charlson Comorbidity Index scores. PICS was associated with requiring mechanical ventilation in four studies. Meta-analysis showed a 34.4 mg L-1 higher C-reactive protein (95% confidence interval [CI] 12.7-56.2 mg L-1; P<0.01), a 4.4 g L-1 lower albumin (95% CI 0.5-8.3 g L-1; P<0.01), and a 0.36×109 L-1 lower lymphocyte count (95% CI 0.25-0.47×109 L-1; P=0.01) in the PICS compared with the non-PICS group. There are a large variety of other potential biomarkers but limited validation studies. The overall quality of evidence is limited, and these results should be interpreted accordingly.
CONCLUSIONS: While older patients and those with co-morbidities could be at greater risk for PICS, acquired risk factors, such as injury severity, are potentially more predictive of PICS than intrinsic patient characteristics. There are many potential biomarkers for PICS, but limited validation studies have been conducted. Persistent myeloid-derived suppressor cell expansion, the continual release of danger-associated molecular patterns and pathogen-associated molecular patterns propagating inflammation, and bioenergetic failure are all mechanisms underlying PICS that could offer potential for novel biomarkers and therapeutic interventions.
CLINICAL TRIAL REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO; CRD42023427749).
This study is being done to determine the effects (good or bad) of Lisinopril (high blood pressure medication) in controlling high blood pressure and improving kidney function for women after delivery who had preeclampsia while they were pregnant .Preeclampsia is a condition that can occur during pregnancy, up to 6 weeks post partum, where the mother's blood pressure is high and protein is present in the urine. This can be dangerous for both the mother and fetus. Although the blood pressure usually returns to normal after delivery, elevated pressures may continue. Normally medication is given when you continue to have high blood pressure after delivery. High blood pressure can cause damage to the kidneys. Lisinopril is a medication that can be used to treat high blood pressure after delivery. Lisinopril offers kidney protection in patients diagnosed with diabetes. We currently do not know if lisinopril can offer the same kidney protection in women diagnosed with preeclampsia. Considering that 10% of all pregnant women develop preeclampsia, the number of women who may eventually develop end stage kidney disease is relatively large and any relatively safe and easy means to prevent this disease would be beneficial.
Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
1.
    Add the prescribed amount of COLESTID or FLAVORED COLESTID to a glassful (three ounces or more) of water or the beverage of your choice. A heavy or pulpy juice may minimize complaints relative to consistency.
2.
    Stir the mixture until the medication is completely mixed. (COLESTID and FLAVORED COLESTID will not dissolve in the liquid.) COLESTID and FLAVORED COLESTID may also be mixed with carbonated beverages, slowly stirred in a large glass; however, this mixture may be associated with GI complaints.

Rinse the glass with a small amount of additional beverage to make sure all the medication is taken.
BACKGROUND: Few studies have examined associations between maternal epigenetic age acceleration and adverse birth outcomes, and none have investigated paternal epigenetic age acceleration. Our objective was to assess the associations of parental (both maternal and paternal) epigenetic age acceleration in relation to birth outcomes.
METHODS: Parental epigenetic age was estimated using seven established epigenetic clocks in 2198 mothers and 2193 fathers from the Norwegian Mother, Father, and Child Cohort Study (MoBa). Individual epigenetic age acceleration was then calculated as residuals from linear regressions of estimates from the epigenetic clocks on chronological age. Further, linear regression was used to analyze differences in continuous outcomes (gestational length and standardized birthweight), while logistic regression was used for binary outcomes (preterm birth, post-term birth, small-for-gestational age [SGA], large-for-gestational age [LGA], and pre-eclampsia), adjusting for chronological age, parity, educational level, smoking, and BMI.
RESULTS: Increasing maternal, but not paternal, epigenetic age acceleration was associated with decreased gestational length for five out of six clocks, with adjusted estimates ranging from a mean 0.51-day decrease (95% CI - 1.00, - 0.02; p-value 0.043) for the Horvath clock to a 0.80-day decrease (95% CI - 1.29, - 0.31; p-value 0.002) for the Levine clock. An association with increasing maternal epigenetic age acceleration according to the DunedinPACE clock was also seen with greater standardized birthweight [mean difference 0.08 (95% CI 0.04, 0.12; p-value < 0.001]. These results were also reflected in an increased risk of spontaneous preterm birth and LGA. No associations were observed with post-term birth, SGA, or pre-eclampsia.
CONCLUSIONS: Maternal, but not paternal, epigenetic age acceleration is associated with shorter pregnancies and an increased risk of spontaneous preterm birth. This may suggest that women's biological age acceleration, including factors such as metabolic and physiologic state, is an additional risk factor for preterm delivery, beyond chronological age.
The invention discloses a traditional Chinese medicine composition capable of improving ovarian function damage caused by chemotherapeutic drugs, and a preparation method and application thereof, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 3-30 parts of mulberry, 4-40 parts of kudzu root, 5-50 parts of poria cocos and 5-50 parts of medlar. A method of preparing a traditional Chinese medicine composition comprising: weighing radix Puerariae and Mori fructus, decocting in water, collecting decoction, filtering the decoction, and precipitating with ethanol to obtain extract No. 1; weighing Poria and fructus Lycii, decocting in water, collecting decoction, filtering the decoction, and precipitating with ethanol to obtain extract 2 #; and mixing the extract No. 1 and the extract No. 2 to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition is applied to improving ovarian endocrine dysfunction and ovarian fertility dysfunction caused by chemotherapeutic drugs. The traditional Chinese medicine composition provided by the invention reasonably combines the four flavors of the traditional Chinese medicines according to the guiding thought of homology of medicine and food in traditional medicine, and has the functions of ascending, descending, sinking and floating, and assistant and guide. Has the effect of relieving ovarian function damage caused by chemotherapeutic drugs.
Vascular calcification is quite common in patients with end-stage chronic kidney disease and is a major trigger for cardiovascular complications in these patients. These complications significantly impact the survival rate and long-term prognosis of individuals with chronic kidney disease. Numerous studies have demonstrated that the development of vascular calcification involves various pathophysiological mechanisms, with the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) being of utmost importance. High phosphate levels, bone morphogenetic protein 2 (BMP2), and runt-related transcription factor 2 (RUNX2) play crucial roles in the osteogenic transdifferentiation process of VSMCs. This article primarily reviews the molecular mechanisms by which high phosphate, BMP2, and RUNX2 regulate vascular calcification secondary to chronic kidney disease, and discusses the complex interactions among these factors and their impact on the progression of vascular calcification. The insights provided here aim to offer new perspectives for future research on the phenotypic switching and osteogenic transdifferentiation of VSMCs, as well as to aid in optimizing clinical treatment strategies for this condition, bearing significant clinical and scientific implications.
BACKGROUND: Assess the current and potential indications of photobiomodulation (PBM) therapy and their level of evidence in the prevention or treatment of side effects related to oncology treatments (radiation therapy, and to a minimal extent favored and hematopoietic stem cell transplants). And report on the recommended modalities (parameters and doses) of PBM therapy.
MATERIALS AND METHODS: The Embase, Medline/PubMed, Cochrane, EBSCO, Scopus, and LILACS databases were systematically reviewed to include and analyze publications of clinical studies that evaluated PBM in the prevention or management side effects related to cancer treatments. The keywords used were "photobiomodulation"; "low level laser therapy"; "acute oral mucositis"; "acute dysphagia"; "acute radiation dermatitis"; "lymphedema"; "xerostomia"; "dysgeusia"; "hyposalivation"; "lockjaw"; "bone necrosis"; "osteoradionecrosis"; "radiation induced fibrosis"; "voice and speech alterations"; "palmar-plantar erythrodysesthesia"; "graft versus host disease"; "peripheral neuropathy"; "chemotherapy induced alopecia". Prospective studies were included, while retrospective cohorts and non-original articles were excluded from the analysis.
RESULTS: PBM in the red or infrared spectrum has been shown to be effective in randomized controlled trials in the prevention and management of certain complications related to radiotherapy, in particular acute mucositis, epitheliitis and upper limb lymphedema. The level of evidence associated with PBM was heterogeneous, but overall remained moderate. The main limitations were the diversity and the lack of precision of the treatment protocols which could compromise the efficiency and the reproducibility of the results of the PBM. For other effects related to chemo/radiation therapy (dysgeusia, osteonecrosis, peripheral neuropathy, alopecia, palmar-plantar erythrodysaesthesia) and haematopoietic stem cell transplantation (graft versus host disease), treatment with PBM suffers from a lack of studies or limited studies at the origin of a weakened level of proof. However, based on these results, it was possible to establish safe practice parameters and doses of PBM.
CONCLUSION: Published data suggest that PBM could therefore be considered as supportive care in its own right for patients treated with radiation, chemotherapy, immunotherapy, hormone therapy or targeted therapies, whether in clinical practice or clinical trials. therapies. However, until solid data have been published on its long-term safety, the use of PBM should be considered with caution and within the recommended parameters and doses, particularly when practiced in areas of known or possible tumours. In this case, the patient should be informed of the theoretical benefits and risks of PBM in order to obtain informed consent before treatment.
NEW MATERIAL:To compound of formula I {R1 is H or lower alkyl; R2 is alkyl or -A-Z-Ar [A is lower alkyl; Z is single bond, O or S; Ar is (substituted) phenyl, thienyl or furyl];R3 is H or OH} or its salt. EXAMPLE:23-Acetylamino-23-demycinosyl-23-deoxydesmycosin. USE:Antibacterial agent against Gram-positive bacteria, etc., remedy for infectious diseases of animals, and feed additive for the prevention of infection and the promotion of growth. It has stronger antibacterial activity than known tylosin. PREPARATION:The amino compound of formula II [R4 is -CHO or group of formula III (R41 and R42 are lower alkyl); R5 is H or -OR6 (R6 is OH-protecting group)] is N-acylated with the carboxylic acid of formula R2-COOH or its reactive derivative to obtain the compound of formula IV. The OH-protecting group of the product is eliminated, and when R4 is group of formula III, the product is subjected to the deacetalization reaction.
Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
The investigators hypothesis is that a diet high in whole-grains reduces abdominal fat. These findings might have clinical and public health significance for reducing obesity and related co-morbidities like type 2 diabetes and cardiovascular disease. Using a double-blind cross-over design, energy expenditure, body composition and metabolic health will be assessed. Three day inpatient study visits to the Cleveland Clinic Clinical Research Unit (CRU) will be implemented for metabolic control and testing. Total daily energy expenditure will be measured using the doubly labeled water (DLW) method. Body fat and glucose/protein metabolism will be assessed by imaging and isotope techniques, respectively. Blood, urine, and stool samples will also be collected for cardiometabolic and digestive health outcomes. After baseline testing, subjects will begin an 8 week dietary intervention, where all food and non-water beverages will be supplied by the study center. Dietary compliance will be assessed by weigh back measurements two times a week. To assess time course effects of diets differing in the amount of fiber on body composition and metabolic health, subjects will provide plasma and urine samples 2, 4, and 8 weeks after initial testing. Imaging and isotope analysis will be performed baseline and at week 8. All post testing will be conducted after week 8 following similar pre-testing control conditions. Subjects will then undergo an 8-10 week washout period where they will be instructed to return to their normal diet (except for any supplements). After the washout period, subjects will start the second arm of the intervention and consume the alternate diet (i.e. refined or whole grain diet). All energy expenditure, body composition and metabolic testing procedures will be repeated during the alternative arm of the study as described above.
The study is a randomized control studies which aims to contribute data to a previous study on the effects of ankyloglossia (tongue-tie) on breastfeeding, and to also provide new information on the effects of maxillary lip-tie on breastfeeding. Participants who are determined eligible for the study (classified to have ankyloglossia via the HATLFF and either a Class III or IV maxillary labial frenum) will be randomly assigned to one of two groups: Group A or Group B. Group A will receive a sham procedure for intervention #1 and a lingual frenotomy procedure for intervention #2. Group B will receive a lingual frenotomy procedure for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy, and breastfeeding will be monitored afterwards. These results will be analyzed to determine when lingual frenotomies, labial frenotomies, or both are necessary to improve breastfeeding pain and LATCH scores.

The study aims to prove that the simple and low risk frenotomy procedure should be considered as treatment for both ankyloglossia and maxillary lip-tie, preventing breastfeeding complications as well as many other future problems such as with speech and self esteem. It is hypothesized that the use of frenotomies as treatment for ankyloglossia and maxillary lip-tie will improve breastfeeding success for breastfeeding couplets with newborns with both ankyloglossia and maxillary lip-tie. It is expected to see an increase in LATCH score to \>7 for breastfeeding sessions and a significant decrease in scoring on the pain scale after frenotomy intervention, while it is expected to see little change in LATCH and pain scale assessment scores after sham procedures. Overall data is not expected to vary significantly between Group A and Group B. It is also hypothesized that a lingual frenotomy alone will be sufficient to improve breastfeeding success without the need to also conduct a labial frenotomy.
A topical treatment for skin irritation that uses a spray-on liquid or a rub-on lotion based papain skin treatment for relief of symptoms related to skin irritation. Papain is suspended in a water solution that is spread on the surface of the affected area. The liquid solution ensures that the active ingredient contacts the skin without missing spots as may occur when using dry or powdered skin treatments. The papain is an active ingredient extracted from papaya which relieves the skin irritation caused by sea lice, insect bites, etc. The water solution is used to suspend the papain such that it more completely contacts the affected area, and further to maintain the papain in a fresh and active state. Optionally, aloe vera is included in the solution to increase the soothing effect on the skin in combination with the papain. In another preferred embodiment, citric acid and sodium benzoate are also used to increase shelf life.
PURPOSE: To obtain a fluoride-releasing dental primer composition, comprising a polymerizable acrylic compound, a light activated catalyst and an organic amine hydrofluoride and capable of leaching the organic amine hydrofluoride from the polymer, chelating with dentin and releasing a fluoride. CONSTITUTION: This dental primer composition comprises a polymerizable acrylic compound (especially preferably triethylene glycol dimethacrylate), a light activated catalyst (especially preferably camphorquinone) and an organic amine hydrofluoride (especially preferably cetylamine hydrofluoride). The composition is capable of forming a polymeric material and the organic amine hydrofluoride is leached from the polymeric material to chelate with dentin. Thereby, a fluouide is liberated. A volatile solvent in an amount of at least 50 wt.% based on the composition is preferably further added thereto. The composition can be polymerized on the dentin to coat the dentin with a polymer having at least 9 MPa adhesive strength.